Another Failure For Biohaven’s Troriluzole
Alzheimer’s Study Misses
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
Biohaven Pharmaceutical Holding Company Ltd.’s glutamate modulator troriluzole has failed a Phase II/III study in Alzheimer’s disease, top-line data show.
The product was no better than placebo at 48 weeks as measured by the study's prespecified co-primary endpoints on the...